期刊文献+

2014年中国KRAS基因突变检测室间质量评价 被引量:3

Result of 2014 external quality assessment for KRAS mutation testing
原文传递
导出
摘要 目的为保证KRAS基因突变检测质量,加强所使用试剂和方法的性能验证,本研究对2014年中国KRAS基因突变检测室间质量评价的总体情况及存在问题进行了分析和讨论。方法2014年两次室间质评样本盘均包含5支样本。要求各参评实验室收到样本后在规定的时间内检测样本并将检测结果上传至向中心数据库。依据回报结果计算各实验室和各检测试剂的成绩,汇总和分析每份样本的总体符合率、假阴性率和假阳性率。结果2014年两次室问质评分别收到58份和57份有效回报结果。检测结果完全正确实验室分别为79.31%(46/58)和94.73%(54/57)。阳性样本总体符合率为93.53%(217/232)和96.49%(165/171),阴性样本总体符合率为100%(58/58)和98.25%(112/114)。样本检测假阴性率分别为1.29%(3/232)和0%,假阳性率分别为4.14%(12/290)和3.15%(9/285)。结论各实验室在KRAS基因突变检测总体符合率上有显著提高,但假阳性和假阴性结果是影响KRAS基因突变检测的主要问题。各实验室需要标准化基因突变检测流程,严格执行扩增产物污染防治措施;各试剂厂家需要通过改良试剂探针设计,优化结果判读标准,最终提高KRAS基因突变检测质量。 Objective To evaluate the performance of KRAS gene mutation detection in 2014 external quality assessment (EQA) program and discuss the problems in clinical laboratories. Methods The sample panel of 2014 EQA program contained 5 artificial formalin-fixed, paraffin-embedded (FFPE) samples. The participating laboratories were asked to report their results before the deadline. The scores of EQA and the rate of overall coincidence, false positive and false negative were calculated. Results The EQA program for KRAS testing was set twice a year. In 2014, 58 and 57 valid lab results were submitted respectively. About 79. 31% (46/58)and 94. 73 % (54/57) of the laboratories were correct for all samples. The coincidence rate of positive samples were 93.53% (217/232) and 96.49% (165/171). The coincidence rate for negative ones were 100% (58/58) and 98.25% (112/114 ). The false-negative ratio was 1.29% ( 3/232 ) and 0%. The false-positive ratio was 4. 14% ( 12/290 ) and 3.15% ( 9/285 ). Conclusions The results of 2014 EQA for KRAS gene mutation testing suggested that the performance of laboratories had been improved significantly, however, the false-negative and false-positive results had always been the major problems affecting the accuracy of KRAS mutations testing. Laboratories needed to standardize the testing process and manufacturers should optimize the reagents and the Way of interpretation, to guarantee the performance of KRAS gene mutation detection.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2015年第10期661-665,共5页 Chinese Journal of Laboratory Medicine
关键词 结直肠肿瘤 原癌基因蛋白质类 ras蛋白质类 突变 个体化医学 Colorectal neoplasms Proto-oncogene proteins ras Proteins Mutation Individualized medicine
  • 相关文献

参考文献11

  • 1Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer [ J ]. Cancer Res, 2012,72 ( 10 ) : 2457- 2467.
  • 2Livre A, Bachet JB, Le Corre D. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J]. C Res, 2006,66(8): 3992-3995.
  • 3Livre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [ J ]. J Clin Oncol, 2008,26 (3) : 374-379.
  • 4Normanno N, Tejpar S, Morgillo F, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC [ J]. Nat Rev Clin Oncol, 2009,6(9) : 519-527.
  • 5Ciardiello F, Tejpar S, Normanno N, et al. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia [ J ]. Target Oncol, 2011,6 (3) : 133-145.
  • 6Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls [J]. Mod Pathol, 2011,24(8) : 1090-1100.
  • 7Zhang R, Han Y, Huang J, et al. Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China[ J]. Clin Chem Lab Med, 2014, 52(12) :1851-1857.
  • 8Thunnissen E, Bovre JV, Bruinsma H, et al. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy[ J]. J Clin Pathol, 2011,64(10) : 884-892.
  • 9van Krieken JH, Siebers AG, Normanno N, et al. European consensus conference for external quality assessment in molecular pathology[J]. Ann Oncol, 2013,24(8): 1958-1963.
  • 10Dijkstra JR, Opdam FJ, Boonyaratanakornkit J, et al. Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis[ J]. J Mol Diagn, 2012,14 (3) : 1871-1891.

同被引文献13

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部